Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respirogen Micro-Oxygen for Hypoxia
NCT04870801Phase 1Withdrawn
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Respirogen Micro-Oxygen in hypoxia (2 arms). Primary endpoint: Oxygen saturation at 2 weeks. Planned start Jan 2022; status: withdrawn.
02
Drugs
Respirogen Micro-Oxygen
03
Conditions
hypoxia
Beyond the preview
Go deeper on NCT04870801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870801.